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Abstract
While the etiology of non-familial Parkinson’s disease (PD) remains unclear, there is evidence that increased levels of 
tissue iron may be a contributing factor. Moreover, exposure to some environmental toxicants is considered an additional 
risk factor. Therefore, brain-targeted iron chelators are of interest as antidotes for poisoning with dopaminergic toxicants, 
and as potential treatment of PD. We, therefore, designed a series of small molecules with high affinity for ferric iron and 
containing structural elements to allow their transport to the brain via the neutral amino acid transporter, LAT1 (SLC7A5). 
Five candidate molecules were synthesized and initially characterized for protection from ferroptosis in human neurons. The 
promising hydroxypyridinone SK4 was characterized further. Selective iron chelation within the physiological range of pH 
values and uptake by LAT1 were confirmed. Concentrations of 10–20 µM blocked neurite loss and cell demise triggered by 
the parkinsonian neurotoxicants, methyl-phenyl-pyridinium  (MPP+) and 6-hydroxydopamine (6-OHDA) in human dopa-
minergic neuronal cultures (LUHMES cells). Rescue was also observed when chelators were given after the toxicant. SK4 
derivatives that either lacked LAT1 affinity or had reduced iron chelation potency showed altered activity in our assay panel, 
as expected. Thus, an iron chelator was developed that revealed neuroprotective properties, as assessed in several models. 
The data strongly support the role of iron in dopaminergic neurotoxicity and suggests further exploration of the proposed 
design strategy for improving brain iron chelation.
Keywords Blood–brain barrier · Dopaminergic neurons · Drug design · Hydroxypyridinones · Iron chelators · LAT1 · 
Parkinson’s disease
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BSA  Bovine serum albumin





DM  Differentiation media
FBS  Fetal bovine serum
FGF-2  Fibroblast Growth Factor 2
GDNF  Glial-derived neurotrophic factor
HOPO  Hydroxypyridinone
LAT1  Large neutral amino acid transporter
LDH  Lactate dehydrogenase
Mp  Melting point
MPP+  1-Methyl-4-phenylpyridinium
MPTP  Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
PD  Parkinson’s disease
PFA  Paraformaldehyde
PLO  Poly-l-ornithine
PM  Proliferation media
PKAN  Pantothenate kinase-associated 
neurodegeneration
UDPRS  Unified Parkinson Disease Rating Scale
UV  Ultraviolet
ROS  Reactive oxygen species
RT  Room temperature
SNpc  Substantia Nigra pars compacta
6-OHDA  6-Hydroxydopamine
Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease (AD), 
affecting 1–2% of the population over 65 years of age (de 
Rijk et al. 2000). It has been estimated that the number of 
PD cases will double by 2030 (Dorsey et al. 2007), mak-
ing identification and development of therapeutic agents to 
prevent, halt or slow down the processes associated with 
PD neuropathology an urgent aim. The disease is primarily 
caused by the loss of dopaminergic neurons in the Substantia 
nigra pars compacta (SNpc) (Lees 2009). Although the exact 
etiology of neuronal loss is unclear, several contributing fac-
tors have been suggested, including intracellular deposition 
of abnormally aggregated alpha-synuclein protein (α-SYN) 
that forms a major constituent of so-called ‘Lewy bodies’ 
(Schildknecht et al. 2013). In association with pathological 
α-SYN, both impaired proteostasis and mitochondrial dys-
function have been deemed critical drivers of PD pathogen-
esis (Malkus et al. 2009; Vigouroux et al. 2004; Zabel et al. 
2010). Toxicants like methyl-phenyl-tetrahydropyridine 
(MPTP) can cause human pathology that highly resembles 
PD (Schildknecht et al. 2017). The history of accidental 
poisoning with MPTP, which is a contaminant of some illicit 
drug preparations, has been extensively documented (Wil-
liam Langston 1985). Several environmental agents, such as 
maneb, dieldrin, paraquat or tebufenpyrad have been exam-
ined for potential roles in PD pathology. For some of these 
pesticides, in particular for the piscicide rotenone, a statisti-
cally significant correlation of exposure and disease has been 
found both in epidemiological studies and in animal experi-
ments (Greenamyre and Hastings 2004; Terron et al. 2018).
Following the initial observation by Lhermitte and oth-
ers (Lhermitte et al. 1924) of abnormal accumulation of 
the redox-active biometal, iron within the basal ganglia 
of PD-affected post-mortem brains, the question arose 
whether disrupted iron metabolism is either adaptive or 
disease promoting (Kaur and Andersen 2004). As iron pro-
motes the generation of highly aggressive free radicals via 
the Haber–Weiss cycle/Fenton reaction (Schildknecht et al. 
2013), abnormal accumulation of redox-active metal in the 
brain could play a central role in PD neuropathology. In this 
regard, it was suggested that oxidation of iron to the ferric 
state may drive a vicious circle between excessive pathologi-
cal levels of reactive oxygen species (ROS), and the intracel-
lular deposition of aggregated α-SYN (Febbraro et al. 2012; 
Levin et al. 2009; Schildknecht et al. 2013).
The finding that iron accumulates in SNpc-located dopa-
minergic neurons during PD progression has prompted 
studies for testing whether iron chelation may be capable of 
modifying PD progression (Devos et al. 2014; Dusek et al. 
2016). Recently, a pilot clinical trial assessed the orally 
available 3-hydroxy-4(1H)-pyridinone (3,4-HOPO)-based 
iron chelator, deferiprone (DFP) (Devos et al. 2014). Early-
stage PD patients treated for six months showed decreased 
SNpc iron content, which associated with slowed disease 
progression, indicated by motor scores. In a follow-up study, 
the authors reported that 6–12 months of DFP treatment 
resulted in reduced SN iron levels and also improved Unified 
Parkinson Disease Rating Scale (UPDRS) scores in early-
stage PD patients (Grolez et al. 2015). The authors further 
reported that PD patients with low serum activity levels 
of ceruloplasmin, a ferroxidase enzyme important for iron 
metabolism, responded better to iron chelation therapy. In 
other work, Martin-Bastida and colleagues (Martin-Bastida 
et al. 2017) found that DFP has low efficacy for removing 
iron from the SNpc. The authors further reported only mod-
erate (non-significant) motor symptom improvements in PD 
patients treated with 30 mg/kg deferiprone. The conflicting 
results reported in published literature regarding the clinical 
efficacy of iron chelators against PD-related neurodegenera-
tion calls for further preclinical studies using robust models 
of the disease to validate and assess the mechanisms of neu-
roprotection. Moreover, it calls for efforts to explore other, 
possibly more effective, iron chelators.
Archives of Toxicology 
1 3
The therapeutic efficacy of iron chelators against neuro-
degenerative disease may be further improved by promoting 
their uptake into the brain and by altering their affinity pat-
tern for various relevant ions. With this in mind, we explored 
the anti-PD therapeutic potential of novel hydroxypyridi-
nones (HOPOs) and related structures (Chaves et al. 2018; 
Workman et al. 2015). The compounds, termed SK1-SK5, 
were synthesized and assessed for their ability to attenuate 
dopaminergic neuronal death. As an in vitro screening sys-
tem for assessing the neuroprotective capacity of the com-
pounds, LUHMES cells were used. These human-derived 
mesencephalic neural precursor cells can be differentiated 
into post-mitotic dopaminergic neurons (Schildknecht et al. 
2009; Scholz et al. 2011). Such cells have been frequently 
used in combination with PD-related toxicants to model PD 
neuropathology, including neuronal loss and intracytoplas-
mic protein aggregates (Devos et al. 2014; Efremova et al. 
2015; Gutbier et al. 2018b; Harris et al. 2018; Hollerhage 
et al. 2017; Poltl et al. 2012; Schildknecht et al. 2009; Scholz 
et al. 2011).
The SK compounds were designed to be translocated 
across the blood–brain barrier (BBB) in a similar way as the 
PD drug levodopa, which is transported by the large amino 
acid transporter (LAT1), encoded by SLC7A5 genes (Dick-
ens et al. 2017). As this carrier is known to accept aromatic 
amino acids, an amino acid side chain was added to the het-
erocyclic core structure (Singh and Ecker 2018). The ration-
ale for this design feature was to allow brain penetration in 
high enough concentrations to achieve an anti-parkinsonian 
therapeutic effect, and thereby avoid excessive metabolism 
or side effects in the body periphery. Our screen revealed 
strong neuroprotective properties for one novel chelator in 
particular, the 3-hydroxy-4(1H)-pyridinone termed SK4, 
which validates abnormal levels of iron ions as a target for 




Dibutyryl-cAMP (cAMP), fibronectin, Hoechst bisben-
zimide H-33342, resazurin sodium salt, tetracycline and 
the neurotoxicants 1-methyl-4-phenylpyridinium  (MPP+) 
and 6-hydroxydopamine (6-OHDA) were purchased from 
Sigma-Aldrich (Steinheim, Germany). Recombinant human 
Fibroblast Growth Factor 2 (FGF-2) and recombinant human 
glial-derived neurotrophic factor (GDNF) were purchased 
from R&D Systems (Minneapolis, USA). Erastin was pur-
chased from Selleckchem (Munich, Germany). Chemicals 
for the synthesis of the iron chelator and control compounds 
were purchased from either Sigma-Aldrich (Gillingham, 
UK), Acros Organics (Geel, Belgium) or Fluorochem (Had-
field, UK) and used without further purification, unless oth-
erwise stated.
Synthesis of novel iron chelators
The synthesis and chemical characterization of precursor 
1 (P1: (2L)-3-amino-2-([(tert-butoxy)carbonyl]amino)pro-
panoic acid) and precursor 2 (P2: 3-(benzyloxy)-2-methyl-
1,4-dihydropyridin-4-one) was exactly as described in the 
literature, and is detailed in the supplementary methods and 
supplementary figure S1. Detailed synthesis protocols and 
chemical characterization of the SK compounds are found in 
the supplementary methods and supplementary figures S2–5. 
Exemplary data are provided here on SK4 ((2L)-amino-3-(3-
hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-yl)propanoic 
acid): First 4.9 g (22.66 mmol) of P2 was mixed with 2.9 g 
(14.2 mmol) of P1, and dissolved in water (100 ml) plus eth-
anol (100 ml) containing sodium hydroxide (2 g, 50 mmol). 
The resulting solution was mixed at room temperature (RT) 
for 8 days continuously. The solution was then acidified to 
pH 2.0 by the addition of concentrated hydrochloric acid 
(HCl). Excess solvents were removed under reduced pres-
sure. The resulting residue was mixed with hydrobromic 
acid (48% w/v, 20 ml) and refluxed for 20 min. The solu-
tion mixture was concentrated under reduced pressure, and 
then the resulting solid was dissolved in water (20 ml), fol-
lowed by treatment with charcoal and basified (pH 5.0) by 
adding ammonium hydroxide solution (ammonia water). 
The resulting solution was cooled to 5 °C for 72 h, after 
which the brown crystals were precipitated. The crystals 
were collected, washed with water and dried, rendering the 
titled compound to become pale brown crystals (3.23 g, 
14.27 mmol, 63%). Melting point (Mp): 165–168 oC. 1H-
NMR (400 MHz,  D2O/CF3COOD) δH = 1.90 (s, 3H), 3.85 
(t, J = 7.2 Hz, 1H), 4.07–4.12 (m, 1H), 4.27–4.33 (m, 1H), 
6.44 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H); 13C-NMR 
(100 MHz,  D2O/CF3COOD) δC = 13.4, 49.17, 52.24, 119.54, 
141.59, 143.28, 147.33, 170.96, 176.7. High-resolution 
mass spectrometry (MS) using electron spray ionization 
gave a measured weight (including 1 extra proton (M + H)) 
[M + H] of 213.0866 (theoretical [M + H] is 213.0869 for 
 C9H12N2O4).
Metal binding studies
Metal cation solutions were prepared from their perchlorate 
salts and their concentrations were determined spectropho-
tometrically for  Fe3+ or via colorimetric titrations (for  Cu2+ 
and  Zn2+) with EDTA (Titriplex III, Millipore), in accord-
ance with published protocols (Fish 1988; Skoog and Skoog 
2004). The acido-basic properties (pKa) of ligands SK2, 
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SK3 and SK4 and their affinity for metals were determined 
via potentiometric titrations  (Cu2+,  Zn2+) and spectropho-
tometric titrations versus pH  (Fe3+). The potentiometric 
titrations were carried out in water (I = 0.1 M  NaClO4), in 
accordance with a previously published procedure (Gillet 
et al. 2017), using a 904 DMS Titrando automatic titrator 
system (Methrom AG; Herisau, Switzerland) with a 2-ml 
Dosino 800 burette driven by the TiAmo 2.5 software 
(Methrom AG; Herisau, Switzerland) and a combined glass 
electrode (6.0234.100; long life, Methrom AG; Herisau, 
Switzerland) filled with 0.1-M NaCl. The  Fe3+ complexes 
were already fully formed at pH 2 and could, therefore, 
not be studied via this technique. The potentiometric data 
were refined with the Hyperquad 2008 program (Gans et al. 
1996).
The protonation constants of the ligands SK2, SK3 and 
SK4, and their stability constants with  Fe3+, were deter-
mined by ultraviolet (UV)–visible spectrophotometric 
titrations versus pH, by simultaneously recording pH and 
UV–visible spectra using a Metrohm UV–visible spectro-
photometer (Cary 60 model, Agilent). Between pH =  − 0.5 
and 2, the batch technique was used; while, classical titra-
tions were carried out for pH values between 2 and 12, fol-
lowing a published procedure (Gillet et al. 2017). The ionic 
strength was not fixed at pH < 1 in the batch titrations and no 
decomposition of the ligands was observed, even in strongly 
acidic conditions.
The spectrophotometric data were fitted with HypSpec 
software (Gans et al. 1996), accessible at https ://www.hyper 
quad.co.uk, to calculate the protonation constants of the 
ligands, the stability constants (log ß) of the formed species 
and the co-ordination model of the studied systems. The data 
for  Fe3+,  Cu2+ and  Zn2+ hydrated species and their solubility 
products were taken into account in the equilibrium model 
(Baes and Mesmer 1986).
Cell culture
LUHMES cells have a normal human genome, a dopamin-
ergic phenotype, neurotypical electrophysiological proper-
ties and sensitivity to PD-related neurotoxicants, including 
rotenone, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP) and its metabolite  MPP+. Handling of LUHMES 
cell cultures was performed as previously described (Gutbier 
et al. 2018a; Scholz et al. 2011). Briefly, the conditionally 
immortalized cells were maintained in proliferation medium 
(PM) that consisted of advanced Dulbecco’s Modified Eagle 
Medium (DMEM)/F12, 2 mM l-glutamine, 1xN2 supple-
ment (Invitrogen, CA, USA) and 40-ng/ml FGF-2, and were 
kept in a 5%  CO2/95% air atmosphere at 37 °C. Cells were 
passaged every other day. For differentiation, 8 million cells 
were seeded in a Nunclon T175 tissue culture flask pre-
coated with 50-µg/ml poly- l -ornithine (PLO) and 1-µg/ml 
fibronectin in water. After 24 h, the medium was changed 
to differentiation medium (DM), consisting of advanced 
DMEM/F12 supplemented with 2-mM l -glutamine, 1 × N2, 
2.25-µM tetracycline, 1-mM dibutyryl 3′,5′-cyclic adenosine 
monophosphate (cAMP) and 2-ng/ml recombinant human 
GDNF. After 48 h, cells were trypsinised and seeded at a 
density of 1.5 × 105 cells/cm2 into dishes pre-coated with 
50-µg/ml PLO and 1 µg/ml fibronectin in DM.
In vitro neurotoxicity models and compound 
treatment
LUHMES cells, differentiated into mature, post-mitotic 
dopaminergic neurons, were treated with one of the four 
neurotoxicants, to create well-characterized in vitro models 
of PD. Prior to neurotoxicant exposure, cells were treated 
with either an SK or control compound for 1 h before addi-
tion of the neurotoxicant. All compounds (using a stock con-
centration of 50 mM) were easily dissolvable in distilled 
 H2O  (dH2O) without requiring heating. The only exception 
was SK2, where the stock concentration was reduced to 
5 mM, due to poor water solubility of the compound. SK 
and control compounds were applied to the cells at concen-
trations which ranged from 12.5 to 500 µM under standard 
incubator conditions (37 °C in a humidified 95% air, 5% 
 CO2 atmosphere).
Following the preincubation period with a compound of 
interest, cells were treated with the parkinsonian mimetic, 
 MPP+, the active metabolite of MPTP, which induces dopa-
minergic neuronal toxicity by inhibiting mitochondrial com-
plex I activity (Dauer and Przedborski 2003).  MPP+ (5 µM, 
Sigma), dissolved in  dH2O, was applied to the cells for 72 h 
before further assessments.
Cells were also treated with the neurotoxicant 6-OHDA, 
which is relatively selective for uptake by dopaminergic neu-
rons due to the high affinity such neurons’ plasma membrane 
transporters hold for this molecule (Luthman et al. 1989). In 
this neurotoxicant-induced model of cell death, neurodegen-
eration occurs principally by means of excessive generation 
of ROS, to ultimately evoke oxidative stress-related cytotox-
icity (Blum et al. 2001). After the compound preincubation 
period, cells were treated with 100-µM 6-OHDA (Sigma-
Aldrich), dissolved in  dH2O. Cells were toxin-treated for 
18 h, before further measures were taken.
Ferroptosis, a non-apoptotic form of iron-dependent cell 
death that occurs due to lethally high levels of lipid hydrop-
eroxides (Stockwell et al. 2017) was initiated via application 
of the ferroptosis activator, erastin (Eradicator of RAS and 
Small T antigen-expressing cells). Similar to the other toxin 
cellular conditions, either an SK or a control compound was 
pre-applied to the cells for 1 h before exposure to erastin 
(which lasted 24 h). Erastin was applied to the cells at a con-
centration of 1.25 µM [10-mM stock in dimethyl sulfoxide 
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(DMSO)], prediluted to 1:800, with the final concentration 
applied to the cells that was 1:10.
Finally, iron-mediated cell damage was initiated by the 
addition of ferrous sulfate. The cells were pretreated with 
an SK compound for 1 h.  Fe2+SO4 was then added for a 
period of 4 days, after which viability was assessed via the 
Resazurin reduction assay. Neuronal morphology was also 
determined by staining the cells with an anti β-III-tubulin 
antibody (Sigma, rabbit, 1:1000) and then a secondary anti-
body (1:1000, anti-rabbit IgG Alexa Fluor 555; Invitrogen) 
for fluorescent (yellow) detection.
General cell viability endpoints
Resazurin: Metabolic activity was detected by means of a 
resazurin reduction assay. Briefly, resazurin solution was 
added to the cell culture medium to obtain a final concen-
tration of 10 µg/ml. After incubating for 30 min at 37 °C, 
the fluorescence signal was measured at an excitation wave-
length of 530 nm, using a 590-nm long-pass filter to record 
the emission. Fluorescence values were normalized by set-
ting fluorescence values of untreated wells as 100%.
LDH release: In a separate assay, lactate dehydrogenase 
(LDH) activity was measured in the supernatant and in the 
corresponding cell homogenates. After the media had been 
transferred into separate plates, cells were lysed in PBS/0.1% 
Triton X-100 for 2 h. A total of 20 μl of sample was then 
added to 180 µl of reaction buffer containing nicotinamide 
adenine dinucleotide (NADH, 100 μM) and sodium pyruvate 
(600 μM) in potassium phosphate buffer (pH 7.4). Absorp-
tion at 340 nm was measured at 37 °C in 1-min intervals 
over a period of 15 min. The slope of NADH consumption 
was calculated. The ratio of  LDHsupernatant/LDHtotal was cal-
culated using the slopes of supernatant and homogenate. 
Control data were subtracted from LDH values. Final LDH 
release data is expressed as percentage of total LDH.
Neurite area as an indicator of cell viability
Calcein-AM: Labeling of live cells was performed with 
1-µM Calcein-AM / 1-µg/ml Hoechst H-33342 for 30 min 
at 37 °C. Images were collected in two different fluores-
cent channels using an automated microscope (Array-Scan 
VTI HCS Reader; Thermo Fisher, PA, USA). Analysis 
was performed by epifluorescence imaging using an auto-
mated microplate-reading microscope (ArrayScan VI HCS 
Reader, Cellomics, Pittsburgh, PA, USA) equipped with a 
Hamamatsu ORCA-ER camera (resolution 1024 × 1024; 
run at 2 × 2 binning). Nuclei were identified as objects 
using channel 1 (365 ± 50/461 ± 15 nm) and according to 
their average size, area, shape and intensity. The calcein 
signal was detected in channel 2 (475 ± 40/525 ± 15 nm). 
An algorithm quantified all calcein-positive cells as viable 
and only Hoechst H-33342-positive nuclei as “not via-
ble” cells. For evaluating the neurite areas, nuclei masks 
were first determined in channel 1, and then expanded and 
transferred to channel 2. All calcein-positive pixels lying 
outside of these masks (somatic area) were counted as 
neurite area.
Three‑Dimensional neuronal organoids
Three-Dimensional (3D) neuronal organoids were generated 
by differentiating LUHMES cells for two days, as described 
for LUHMES cell culturing. On day 2 of differentiation, 
cells were detached and seeded in round-bottom ultra-low 
attachment 96-well plates (#7007, Corning Costar) at a cell 
density of 5000 cells/well in 100-µl LUHMES differentia-
tion medium (DM). To facilitate spheroid formation, plates 
were centrifuged at RT for 5 min at 300 × g. Organoids 
formed spontaneously from the cell pellets within 48 h. Half 
medium was changed every 2–3 days. On day 8 of differen-
tiation, LUHMES organoids were plated on Matrigel-coated 
(1:200) 96-well plates (#83.3924, Sarstedt) to allow neurite 
outgrowth. After 48 h, plated organoids were treated with 
the ferroptosis-inducer, erastin for 24 h, with or without 1 h 
pre-treatment with ferrostatin-1, the established neuropro-
tective iron chelator desferoxamine (DFO) (Poltl et al. 2012), 
or SK4, which the initial neuroprotective screen highlighted 
as a lead compound. Cell viability was determined using 
calcein-AM (1 µM) staining, while neurite area was deter-
mined by means of propidium iodide (1 µg/ml) staining, the 
staining reagents that were applied for 1 h. Mosaic fluores-
cent images were then taken of the cells using automated 
microscopy (Axio Observer A1, Carl Zeiss, Germany), 
which utilized an objective size 5x/0.15 EC Plan-Neofluor. 
Twelve images per well were taken and stitched together 
using Zeiss “Zen” imaging software (version 1.1.2.0, Blue 
edition). Images were analyzed using ImageJ software (ver-
sion 1.51 s, Rasband, U.S. National Institutes of Health). 
Neurite area was calculated as the total neurite area, and cell 
viability as the relative propidium iodide fluorescence inten-
sity to a positive 100% dead control (0.5% Triton-X100).
For immunostaining, plated spheres were fixed on an 
8-well µ-slide (#80,826, Ibidi, Germany) with 4% paraform-
aldehyde (PFA) for 1 h at RT. After washing with phosphate-
buffered saline (PBS), specimens were permeabilized with 
0.6% Triton-X100 for 30 min at RT. Subsequently, they 
were blocked with blocking buffer (5% fetal bovine serum 
(FBS) and 0.1% Triton-X100 in PBS). Anti-NF200 primary 
antibody (#N0142, Sigma) was applied diluted in block-
ing buffer (1:1000) overnight at 4 °C. After washing with 
PBS, secondary antibody (#A2112, anti-mouse IgG1 Alexa 
Fluor 555, Invitrogen) was applied diluted in blocking buffer 
(1:1000) for 1 h at RT. Images were recorded with a Zeiss 
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LSM 880 confocal microscope (40×/1.4 Plan apochromat, 
oil based) and processed in ImageJ.
LAT1‑mediated uptake and trans‑stimulation assay
HEK293 cells, stably expressing pcDNA3.1 V5-6xHis (con-
trol) or pcDNA3.1 SLC7A5-V5-6xHis (LAT1), were gener-
ated and cultured in DMEM containing 10% FBS (Dickens 
et al. 2013, 2017). HEK293 control and HEK293 LAT1 cells 
were plated 24 h before the transport assays were performed. 
The wells were washed with transport buffer [Hank’s buff-
ered saline solution + 25 mM HEPES + 0.1% w/v bovine 
serum albumin (BSA) at pH 7.4] pre-warmed to 37 °C. 
3[H]-phenylalanine [American Radiolabeled Chemicals 
(ARC), St. Louis, MO, USA] at a radiotracer concentration 
of 0.15 µCi/ml and unlabelled phenylalanine (ARC), giving 
a final concentration of 1 µM, was included in the transport 
buffer. This was added to the cells for 3 min at 37 °C in the 
absence/presence of 1-mM leucine, SK4 or SK4C2. At the 
end of the uptake assay the cells were washed 3 × with ice-
cold transport buffer. Cell lysis was carried out by adding 
5% w/v sodium dodecyl sulfate (SDS) for at least 15 min at 
37 °C. Liquid scintillation (LS) counting on the cell lysates 
was performed with a 1500 Tri Carb LS counter (Pack-
ard Instrument Company, Germany). The LAT1-mediated 
uptake of phenylalanine is determined by subtracting the 
uptake of HEK293 control cells from HEK293 LAT1 cells. 
The data values were converted to percentages by normal-
izing to the average uptake in the vehicle treated cells.
Trans-stimulation is similar to the uptake assay except that 
the HEK293 LAT1 cells were preloaded for 3 min at 37 °C 
with transport buffer containing 1-µM 3[H]-phenylalanine as 
a radiotracer. The cells were then washed with pre-warmed 
transport buffer, after which SK4 (1 mM) was incubated with 
the cells for 3 min. Under such conditions, external LAT1 
substrates are transported into cells, while LAT1 substrates 
are exported from cells as part of the overall antiporter trans-
port cycle. Cell washing, lysis and scintillation counting were 
then performed similar to what is described (Dickens et al. 
2013, 2017) for performing the uptake assay.
Electrochemical detection of nitric oxide
Interaction of the SK compounds with nitric oxide (·NO) 
was detected by the application of a ·NO-sensitive electrode 
(AmiNO-700, Innovative Instruments, Tampa, FL, USA), 
as previously described (Schildknecht et al. 2011). The SK 
compounds (50 µM in 10-mM PBS, pH 7.4,) were incu-
bated with the ·NO-donor Spermine-NONOate (10 µM) 
(Cayman Chemicals, Ann Arbor, MI, USA). Measurements 
were performed in glass tubes at 37 °C, and all samples 
contained 100-µM desferoxamine to exclude any contribu-
tion of iron to the observed effects. As the release of ·NO by 
Spermine-NONOate is temperature dependent, the freshly 
prepared ice-cold Spermine-NONOate was injected into 
pre-warmed (37 °C) PBS/compound mixture (990 µl). This 
procedure leads to an almost linear increase in ·NO release 
within the first few minutes after injection, followed by 
a steady-state phase, characterized by a slow but gradual 
decline in ·NO release in consequence to Spermine-NONO-
ate’s half-life time of ca. 45 min (Maragos et al. 1991). In the 
present experiment, the initial linear increase was detected. 
As positive controls, we used xanthine oxidase (1 mU/ml) 
together with its substrate hypoxanthine (500 µM), a super-
oxide-generating system.
Interaction of SK compounds with superoxide 
or peroxynitrite
With the experiments conducted in 96-well plates, interaction 
between the SK compounds (50 µM) and superoxide was 
monitored as the oxidation of dihydroethidium (DHE) (5 µM, 
Sigma-Aldrich). SK compound interaction with peroxyni-
trite was monitored by detecting dihydrorhodamine (DHR) 
123 (1 µM, Sigma-Aldrich) oxidation in PBS (10 mM). Per-
oxynitrite was generated by Sin-1 (50 µM), superoxide was 
generated by xanthine oxidase (1 mU/ml) (Sigma-Aldrich) in 
combination with its substrate, hypoxanthine (500 µM, LKT 
Laboratories, St. Paul, MN, USA). Freshly prepared Sin-1 or 
xanthine oxidase was stored on ice and added to pre-warmed 
buffer/compound for 20 min at 37 °C. Fluorescence of DHR 
123 (λex = 485 nm, λem = 538 nm) and DHE (λex = 485 nm, 
λem = 575 nm) was read using a TECAN Infinite 200 micro-
plate reader (Männedorf, Switzerland).
Interaction of SK compounds with hydroxyl (·OH) 
radicals
In 96-well plates, hydroxyl radicals (·OH) were generated by 
combining  FeSO4 (20 µM) and  H2O2 (50 µM) in  H2O. For 
the readout, desoxyribose (5 mM) was added for the interac-
tion with ·OH to form malondialdehyde. The SK compounds 
and desferoxamine, were added at the concentrations indi-
cated in the graphical display of the data and incubated for 
15 min at RT. The amount of malondialdehyde formed was 
then detected by the combination of 1/3 volume sample mix, 
1/3 volume trichloroacetic acid (2.8 g/100 ml) and 1/3 vol-
ume of thiobarbituric acid (1 g in 100 ml of 50 mM NaOH). 
The mixture was boiled for 20 min at 95 °C. Absorption was 
then measured at 532 nm.
Data handling and statistics
If not mentioned otherwise, all data values are expressed as 
means ± the standard deviation (SD). If not indicated other-
wise, experiments were performed at least three times (i.e., 
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using three different cell preparations), with at least three tech-
nical replicates per condition. Statistical methods for analyzing 
the various data sets are indicated directly in the figure legends.
Results
Design rational of novel iron chelators
Here, we used the structure of the LAT1 substrate L-DOPA, 






Amino acid side chain
essential for BBB penetration


















Fig. 1  Design hypothesis for novel iron chelators. Iron chelators char-
acterized in this study were designed for both optimized iron co-ordi-
nation and enhanced blood brain barrier transport. a All compounds 
have two substructures with different function: (i) a group essential 
for the iron co-ordination (red) and (ii) the amino acid side chain to 
facilitate LAT1-mediated uptake into endothelial cells of the BBB 
(blue). b Acronyms, structures and molecular weights of all chelators 
tested within this study. c Design of proof-of-concept control com-
pounds. SK4C1 and SK4C2 are derivatives of SK4 with a functional 
inactivation of one of the substructures depicted in a. SK4C1 has a 
methoxy group (in place of the hydroxy), which inhibits iron chela-
tion and SK4C2 is a primary amine (not an amino acid), which is not 
transported by LAT1 (color figure online)
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for designing brain-permeable iron chelators. For this pur-
pose, the aromatic ring of L-DOPA (catechol group) was 
replaced by a metal chelator moiety, which is similar to 
DFP (Fig. 1a). We hypothesized that such modified amino 
acids will remain LAT1 substrates and should have clinically 
favorable CNS-targeting properties. Further structural vari-
ations were introduced to some compounds to change their 
susceptibility to enzymatic inactivation by methylation or 
glycosylation. Thus, the compounds SK1-5 were designed 
and synthesized (Fig. 1a, b, S1-4). In addition, two variants 
of SK4 were designed and produced to provide analogs lack-
ing chelation properties (SK4C1) or LAT1 affinity (SK4C2) 
(Fig. 1c; S5).
Protection of neurons from erastin‑induced 
ferroptosis
We used a cellular model of programmed cell death medi-
ated by endogenous cellular iron for bioactivity profiling. 
Ferroptosis (Dixon et al. 2012) was triggered by erastin. 
This model compound was chosen for the initial screen, as 
it neither affects iron directly, nor is it known to damage 
any cellular structures directly (Yang et al. 2014). SK2 and 
SK4 both protected neurons to a similar extent as DFP, as 
assessed by the test endpoints resazurin reduction, neurite 
area and LDH release. SK3 was active, but less potent; SK1 
and SK5 completely lacked the ability to protect neurons 
from ferroptosis following erastin exposure (Fig. 2a–g). The 
modifications of SK4 showed the expected properties; in this 
regard, SK4C1, which lacks any metal chelation properties, 
did not protect neurons against erastin toxicity. In addition, 
SK4C2, which represents the structural modification to dis-
turb LAT1 transport, retained similar in vitro bioactivity as 
SK4 (Fig. 2a, d, f).
Biologically relevant features different from iron 
chelation
The adverse effects of free iron ions in biological systems 
can be mediated by oxidative stress (Monzani et al. 2019). 
Therefore, antioxidants often act as false positives in drug 
discovery programs for identifying effective iron chelators. 
While antioxidant properties may provide added value to an 
anti-neurodegenerative drug, one has to be careful during the 
initial stages of profiling the drug’s properties not to mis-
take a drug’s protective properties for iron chelation potency. 
We, therefore, profiled the ability of the SK compounds to 
directly (independent of iron chelation) scavenge superox-
ide, nitric oxide, peroxynitrite and hydroxyl radicals. None 
of the tested compounds reacted with superoxide or nitric 
oxide (Fig. 3a, b). However, DFP, SK2 and SK4 proved to 
be peroxynitrite scavengers of similar potency, but clearly 
less potent than the more well-known scavengers, urate and 
ascorbate.
Two promising drug candidates, SK2 and SK4, were fur-
ther profiled in a hydroxyl radical scavenging assay. SK2 was 
significantly more potent than SK4. Its activity was in a sim-
ilar range to that of DFO, an iron scavenger known to also 
have distinct antioxidant properties (Bartesaghi et al. 2004) 
(Fig. 3a–e). Based on these data, any protection seen with 
SK2 in a complex bioassay (in vitro or in vivo) may be due 
either to specific iron chelation or to unspecific radical scav-
enging. SK4 appeared as a more promising tool compound 
to test for the specific role of iron in neurodegeneration.
To prove the validity of the “LAT1 substrate” design 
hypothesis, we assessed the properties of SK4 and the con-
trol compound. As expected for a LAT1 substrate, SK4 com-
peted strongly with the phenylalanine uptake of cells over-
expressing LAT1, and significantly increased the export of 
phenylalanine from preloaded cells in the trans-stimulation 
assay. SK4C2 (same iron chelator features as SK4, but lack-
ing the amino acid group to be recognized by LAT1) was not 
transported at all (Fig. 4a, b).
Direct iron‑chelating properties of SK4
SK4′s chelation properties towards Fe(III), Cu(II) and Zn(II) 
were determined by spectrophotometric titrations versus pH 
and compared to the reference standard DFP. As the basis 
for this, the protonation constants (pKa values) of SK4 were 
determined (Fig. S6), as chelation properties are dependent 
on the protonation state of the chelator, and as pKa values 
for various HOPO-related structures are known to show a 
broad range of variation (Fig. S7). The co-ordination mod-
els and stability constants of the formed complexes with 
metals (Fe(III), Cu(II) and Zn(II)) were then determined 
and the chelation potency/efficacy (displayed in terms of 
non-complexed metal remaining in solution  (log[Mn+]nc) 
Fig. 2  Protection of neurons from erastin-induced ferroptosis by 
SK compounds. a Differentiated LUHMES neurons were treated on 
day 6 (d6) with erastin (1.25 μM) in the presence or absence of SK4 
(200 μM) or deferiprone (DFP; 200 μM). After 24 h, the cells were 
stained with calcein-AM (green stain of live cells) and H-33342 (red 
stain for live and dead cells). Representative images are shown. The 
width of one image corresponds to 300  μm of the original cultures 
b/c: Neuroprotection against erastin-induced ferroptosis of LUHMES 
(d6) cells was tested as in a, but resazurin reduction was used as 
quantitative endpoint. D/E: Experiments were performed as described 
in a–c, but neurite integrity was quantified by automated microscopy 
as alternative endpoint f/g: Experiments were performed as described 
in a–e, but the release of lactate dehydrogenase (LDH) was measured 
as death endpoint. Data are means + SEM of three independent exper-
iments (color figure online)
◂
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was calculated under defined conditions (20-µM chelator, 
1-µM metal ion) within the range of pH values relevant for 
cells (pH 5.5–pH 8) (Fig. 5a). SK4 showed stronger complex 
formation with  Fe3+ than DFP (Fig. 5a), but exhibiting the 
same 3,4-HOPO complexing moiety, especially at higher pH 
values (as found e.g. within mitochondria). SK4 also showed 
affinity for  Cu2+ ions, but almost none for  Zn2+. Data were 
also obtained for compound SK3, based on the 1,2.HOPO 
scaffold, to exemplify the pH dependence of complex forma-
tion with  Fe3+. The lower pKa values of this ligand favor its 
chelation properties at lower pH values.
Physicochemical studies in simple medium (0.1-M 
 NaClO4 in this study) give critical information about the 
metal-chelating ability of ligands, but those cannot be 
extrapolated to complex biological systems (cells; brain) 
without caution. We, therefore, also tested the chelation 
capacity of SK2 and SK4 in a cellular model. Neuronal 
cultures were exposed to a  FeSO4 solution, known to trig-
ger cell death. SK4 protected neurons from iron-induced 
neurodegeneration. SK2 did not protect the neurons under 
similar conditions (Fig. 5b, c), in accordance with its lack 
of iron chelation capabilities under these experimental con-
ditions. In this direct iron exposure test, the biological fea-
tures (= cell protection) of SK4 and SK2 were obviously 
very different. Moreover, the radical scavenging property 
of SK2 was not of sufficient relevance to protect cells from 
externally added iron ions.
Protection of neurons from  MPP+ toxicity by SK 
compounds
We further characterized the compounds in the well-estab-
lished parkinsonian MPTP/MPP+ model. As reported previ-
ously (Krug et al. 2014), dopaminergic neurons exposed to 
5 μM of the mitochondrial toxicant  MPP+ undergo apoptosis 
within 72 h, and this cell death can be prevented by iron che-
lators (Poltl et al. 2012). Cell death induced by  MPP+ in our 
model system was assessed by the reduction of the neurite 
area and an increase in LDH release (Fig. 6a). SK2 and SK4 
protected neurons at > 10 µM, and protection was similar to 
that of DFP. SK3 was less potent; whereas, SK1 completely 
lacked the ability to protect neurons from  MPP+-induced cell 
death (Fig. 6b–e). SK4C1 also showed a very poor protect-
ing activity (minor effect at ≥ 200 µM) (Fig. 6b, d). Further-
more, we found in an additional experiment that SK4 and 
DFP rescued dopaminergic neurons even when applied 2 h 
after the toxicant (Fig. S8).
Protection of neurons from 6-hydroxydopamine toxicity 
by SK4.
A further well-established model is based on the incu-
bation of dopaminergic neurons with 6-hydroxydopamine 
(6-OHDA). The corresponding in vivo model shows several 
key characteristics of neurodegeneration in PD (Lindholm 
et al. 2007; Salari and Bagheri 2019; Ungerstedt 1973). The 
damage initiated by 6-OHDA involves oxidative stress to 
neurons, with endogenous iron levels being important con-
tributors to this damage mechanism (Shachar et al. 2004; 
Workman et al. 2015; Youdim et al. 2004). When neurons 
were incubated with 6-OHDA, cells lost their neurites within 
24 h; while, somata stayed intact and viable (Fig. 7a). This 
specific neurite degeneration was significantly reduced by 
SK4 (≥ 100 µM) and DFP (≥ 50 µM) (Fig. 7a, b). Also SK2 
reduced the damage (at ≥ 50 µM); at very high concentra-
tions (200 µM), its effect was more pronounced than the 
profile produced by either SK4 or DFP (Fig. 7c). All other 
compounds tested did not show any effect on neurite loss 
following 6-OHDA exposure (Fig. 7b, c).
Protection of neuronal organoids by SK4 
from ferroptosis
To gain insight into the potential protective effect of SK4 on 
the tissue level, we established a 3D neuronal model for eras-
tin-triggered neurodegeneration. Neuronal spheroids were 
generated within 10 days. After complete differentiation and 
neurosphere formation, the organoids were pretreated with 
protective compounds for 1 h and then exposed to erastin for 
24 h (Fig. 8a). To analyze the damage, viable structures were 
visualized by staining with calcein-AM or immunostaining 
of neurofilament heavy chains (NF200). The overall neurite 
area was analyzed to assess putative protective effects by the 
SK compounds (Fig. 8b–d). The anti-ferroptotic agent Fer-1 
(Miotto et al. 2020) protected spheroids from neurodegen-
eration. A similar protective effect was also observed for the 
iron chelators DFO and SK4 (Fig. 80c, d).
Discussion
Here, we present data on the physicochemical characteriza-
tion as well as cellular investigations of novel iron chelators 
produced in our laboratories. Neuroprotective properties 
were investigated using established PD- and iron overload 
in vitro models that utilized human LUHMES neuronal 
cultures. The cells were challenged with various toxicants 
that recapitulate aspects of PD, including dopaminergic cell 
death, oxidative stress and mitochondrial functional defects 
(Schildknecht et al. 2017). Potential iron-chelator drug can-
didates were also protective in a neuronal ferroptosis model, 
as well as in a direct iron overload paradigm. As SK4 con-
sistently provided neuroprotection against various cytotoxic 
conditions, our work suggests that this chemical is a useful 
new tool to further elucidate the mechanistic role of iron 
in neurodegenerative processes. Moreover, it indicates new 
strategies to develop brain-targeted metal chelators.
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Fig. 3  Antioxidant properties of iron chelators. a Interaction of SK 
compounds with superoxide. The SK compounds (50 µM) were incu-
bated with xanthine oxidase (1 mU/ml), hypoxanthine (500 µM), and 
DHE (5  µM) for 20  min. b Interaction of SK compounds (50  µM) 
with nitric oxide was investigated by their incubation with the ·NO-
donor Spermine-NONOate (10 µM) and the detection of free ·NO by 
a ·NO-selective electrode. As positive control, superoxide was gener-
ated by xanthine oxidase/hypoxanthine to quench ·NO. c + d Interac-
tion of SK compounds with peroxynitrite was investigated by appli-
cation of the peroxynitrite-generating compound Sin-1 (50  µM). As 
readout, DHR 123 (1 µM) was added, its oxidation was followed by 
the detection of Rhodamine fluorescence. Desferoxamine and defer-
riprone (DFP) were tested as alternative iron chelators, uric acid and 
ascorbic acid served as positive controls. e + f Interference of SK 
compounds with  Fe2+/H2O2-derived hydroxyl radical (·OH) gen-
eration. Ferrous iron (20 µM) and  H2O2 (50 µM) were combined to 
allow ·OH generation. As readout, · OH-dependent formation of 
malondialdehyde was assessed. Data are means + SEM of three inde-
pendent experiments. Significance tests were not performed for indi-
vidual data points
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Iron chelators have been deemed therapeutically useful in 
PD and other neurodegenerative conditions (Dunaief 2011; 
Joppe et al. 2019; Kaindlstorfer et al. 2018; Ndayisaba et al. 
2019). However, their exact effects on brain pathophysiology 
have not been fully elucidated. One important hypothesis is 
that the abnormally high labile iron levels in the nigrostriatal 
system of PD patients contribute to a heightened pro-oxidant 
environment that impacts on vulnerable dopaminergic neu-
rons found in the SNpc. In this regard, iron-dependent oxida-
tive stress has been demonstrated in vitro, in parkinsonian 
animal models and also in post-mortem brains of PD patients 
(Devos et al. 2014; Kaur et al. 2003; Ward et al. 2014; Zheng 
et al. 2005). In this context, it is important to note that iron-
dependent pathology may be triggered without additional 
iron to an experimental system or human tissue. Brain cells 
contain mM concentrations of overall iron, mostly bound to 
ferritin (Reinert et al. 2019; Workman et al. 2015). If only 
a small fraction of such iron is mobilized, i.e., transferred 
to the redox-active labile iron pool (LIP), iron-dependent 
toxicity, and an iron-dependent form of programmed death 
termed ferroptosis, can ensue (Stockwell et al. 2017). Alter-
natively, iron can change its role in a cell without increasing 
ferric iron concentrations. When the overall oxidant–anti-
oxidant balance is shifted, normally innocuous iron concen-
trations can take on pathological roles, where this can be 
counteracted again either by activating the cell’s antioxidant 
defence system (Liddell and White 2018) or by the use of 
iron chelators. This background explains why iron plays a 
role in several toxin-based models of mitochondrial impair-
ment and oxidative stress (Poltl et al. 2012; Santiago et al. 
1997). In line with this, SK4 fully protected differentiated 
LUHMES cells against the differently acting toxicants  MPP+ 
and 6-OHDA.
Although it remains unresolved, whether oxidative stress 
can be considered a primary cause of the neuronal death 
seen in neurodegenerative disease patients or as a bystander 
in the progressive neurodegenerative cascade (Andersen 
2004), increased iron levels have been shown to directly 
catalyze ROS production during dopamine synthesis (Rho-
des and Ritz 2008). Many forms of neurodegenerations 
are also accompanied by the production of peroxynitrite 
(Schildknecht et al. 2013). This highly reactive chemical 
species, formed by recombining NO with superoxide, inter-
acts directly with a variety of biological targets to exert irre-
versible damage to all classes of biomolecules (Weidinger 
and Kozlov 2015). As the cellular damage is strongly driven 
by peroxynitrite in some model systems, it is important to 
verify, whether a novel agent can be regarded as a direct 
scavenger of this molecule or other reactive oxygen/nitrogen 
species. However, such issues for complicating interpreta-
tion of compounds’ mechanism of action do not apply to 
LUHMES culture systems. This is since these cells do not 
Fig. 4  SK4 transport by LAT1. The transport of SK4 and SK4C2 by 
LAT1 was assessed in HEK293 cells transfected with human LAT1. 
Radiolabeled 3[H]-phenylalanine was used as established LAT1 sub-
strate. a Cells were exposed to 3[H]-phenylalanine for 3  min in the 
presence or absence of competitors (1  mM). Then, the cells were 
washed, lysed and analyzed for their radioactive content. Uptake 
was normalized to the data obtained in the absence of competitors. 
b In a trans-stimulation assay, HEK293 LAT1 cells were preloaded 
with 3[H]-phenylalanine. Then, they were incubated in the presence 
of potential LAT1 substrates. The known substrate Leu was used as 
positive control of a compound that drives the antiporter transport 
cycle and, thus, accelerates the emptying of cells of LAT1 substrates 
such as phenylalanine. The cell emptying capacity via LAT1 was then 
compared for SK4 and SK4C2. Data are expressed as mean ± SD 
(n = 3) of three independent experiments performed in tripli-
cate. Significantly different from indicated condition: *(P < 0.05), 
**(P < 0.01), ***(P < 0.001), ****(P < 0.0001)
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Fig. 5  Iron chelating properties of SK4. a Chelation power of 
ligands for the studied metals (combinations specified in the graph) 
between pH 5.5 and 8. The y-axis shows the concentration of metal 
non-complexed to the ligand at the given conditions (−  log[Mn+]nc, 
 [L]tot = 0·M,  ([M]tot  = 1·M), taking into account the experimentally 
determined protonation constants of the ligands, the stability con-
stants of their metal complexes, and the hydrolysis constants of the 
metals. Thus, a value of 6 indicates no complexation by the given 
ligand (i.e., a free concentration of the metal ion of 1 µM), while a 
value of 12 indicates that 1 pM is non-complexed. Thus, the higher 
the value, the stronger the chelator. Note that the line for the SK2-
Fe3+ complex is not shown in the diagram, as it runs continuously 
at 6 (no complex formation in the pH range shown). b Protection 
of neuronal cells from iron toxicity. Human dopaminergic neurons 
(LUHMES) were incubated with  FeSO4 (150 µM) and SK2 or SK4 at 
the concentrations indicated for a period of 4 days. For visualization 
of cell morphology, cells were stained with an anti-β-III-tubulin anti-
body. Control cells showed a typical neuronal network with many fine 
neurite processes between the cells.  Fe2+ led to cell loss and clump-
ing of the remaining cells. This was prevented by SK4, but not SK2. 
The width of images corresponds to 200 μm in original cultures. c In 
experiments performed as in b, viability was assessed by the analysis 
of resazurin reduction. Data are means ± D of 3 independent experi-
ments. There was a highly significant statistical difference at 100 µM 
(P < 0.001; ANOVA with Dunnett’s post hoc test)
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produce endogenous peroxynitrite due to their very low NO 
synthase activity (Schildknecht et al. 2015). Thus, our data 
showing that SK4 is not a potent antioxidant is a clear indi-
cation that this compound’s ability to protect against  MPP+ 
and 6-OHDA neurotoxicity must be due to its iron chelation 
effects.
In the area of experimental pharmacology and for proof-
of-concept studies, it is rather important that iron chelators 
have no other targets and activities. This is the only way to 
provide clear evidence for a causal role of iron in neuro-
degeneration models. In this context, the finding that SK4 
does not interact with all major reactive oxygen species is 
of importance. Moreover, the protection from cell death 
in multiple tests by the non-antioxidant iron chelator SK4 
strongly suggests a causal involvement of iron in all these 
models of neurodegeneration. For a novel metal chelator to 
Fig. 6  Protection of neurons from  MPP+ toxicity by SK compounds. 
a Differentiated LUHMES neurons were treated on day 6 (d6) with 
 MPP+ (5 μM) in the presence or absence of SK4 (200 μM) or DFP 
(200 μM). After 72 h, the cells were stained with calcein-AM (green 
stain of live cells) and H-33342 (red stain for live and dead cells). 
Representative images are shown. The width of one image cor-
responds to 300  μm of the original cultures. b/c Experiments were 
performed as described in a, but neurite integrity was quantified by 
automated microscopy as alternative endpoint d/e Experiments were 
performed as described in a–c, but the release of lactate dehydroge-
nase (LDH) was measured as death endpoint. Data are means + SEM 
of three independent experiments
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be regarded as having potential clinical value for treating 
the brain degenerating disorder PD, the drug should inher-
ently possess the ability to effectively cross the BBB. Sev-
eral FDA-approved iron chelators, including deferoxamine 
(Okauchi et al. 2009) and DFP (Boddaert et al. 2007) may 
cross the BBB to some extent. Drugs that accumulate pas-
sively in brain tissue or that are actively transported across 
the BBB are of interest, as long-term iron chelation may 
have adverse side effects in the body periphery. SK1-4 were 
designed to be substrates of the LAT1 transporter, which is 
highly expressed in brain capillary endothelial cells. This 
carrier is responsible for transporting large neutral amino 
acids, including phenylalanine, tyrosine and leucine, across 
the BBB in a sodium-ion-independent manner (Matsuo 
et al. 2000). The same transport system allows transfer of 
the hydrophilic drug levodopa, a precursor for dopamine, 
into the brain (Smith and Takasato 1986), with our com-
pounds that were designed to mimic the chemical features 
of L-DOPA, to be recognized by LAT1. We experimen-
tally validated our structural design hypothesis by show-
ing that SK4 is transported into LAT1 expressing cells. In 
this respect, the SK compound differs from the clinically 
approved iron chelators, desferrioxamine (DFO), DFP, and 
deferasirox (ICL-670), which rather transgress the BBB via 
passive diffusion (Zhou et al. 2012).
Iron chelation therapy has its origins in the treatment 
of iron-overload syndromes such as the thalassemias. For 
these inherited blood disorders, the reduction of an iron 
overload has clearly proven to be clinically beneficial 
(Mobarra et al. 2016). However, the scenario is less clear 
for PD, where clinical trials have only been partially 
successful. One explanation may be that current drug 
delivery methods are not optimized for yielding high 
chelator concentrations in the CNS. More targeted drug 
delivery methods hold clear advantages for improving 
clinical outcomes, including reducing drugs’ side effects 
in the periphery. Our study provides proof-of-concept 
for a novel delivery approach. Other drug properties 
may also play important roles. Each metal chelator has 
a specific “activity” fingerprint, concerning the affinity 
to ferric iron vs ferrous iron vs several other metal ions 
 (Cu+,  Zn2+, etc.), concerning the Ph dependence of such 
Fig. 7  Protection of neurons from 6-hydroxydopamine toxicity by SK 
compounds. a Differentiated LUHMES neurons were treated on day 
6 (d6) with 6-OHDA (100  μM) in the presence or absence of SK4 
(200 μM) or deferiprone (DFP; 200 μM). After 18 h, the cells were 
stained with calcein-AM (green stain of live cells) and H-33342 
(red stain for live and dead cells). Representative images are shown. 
The width of one image corresponds 300 μm of the original cultures 
b/c Neuroprotection against 6-OHDA-induced neuronal damage of 
LUHMES (d6) cells was tested as in a, but resazurin reduction was 
used as quantitative endpoint. Data are means + SEM of three inde-
pendent experiments
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affinities, and the competition with cellular iron-chelat-
ing structures, especially in the active center of metallo-
enzymes. In this regard, it may prove to be a neuroprotec-
tive advantage to inactivate certain prolyl hydroxylases 
by removing their iron (Karuppagounder et al. 2016); on 
the other hand, it may be detrimental to inactivate cata-
lase or mitochondrial respiratory chain complexes. For 
this reason, drug candidates appearing similar in terms 
of their interaction with ferric iron may prove to have 
largely different drug properties. In the absence of more 
information on what the optimal profile should look like, 
it is important to have a large panel of diverse iron che-
lators available for pharmacological studies. The novel 
SK compounds, and in particular SK4, contribute to this 
important objective.
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